Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

TCBP TC BioPharm Holdings PLC

0.00 (0.00%)
最終更新日: 20:22:37
名称 銘柄コード 市場 種別
TC BioPharm Holdings PLC TCBP NASDAQ Depository Receipt
  前日比 前日比 % 現在値 時刻
0.00 0.00% 1.73 20:22:37
始値 安値 高値 終値 前日終値
この銘柄の詳細情報 »


日付 時間 ソース タイトル
2024/4/0421:32PRNUSTCBP Announces Execution of Non-Binding Letter of Intent for..
2024/4/0221:30PRNUSTCBP Increasing Treatment Capacity with Expanded..
2024/3/1921:30PRNUSTCBP Adjourns General Meeting Until a Later Date
2024/3/1821:30PRNUSTCBP Announces Exercise of Series D Warrants For Cash
2024/3/0620:30EDGAR2Form 8-K - Current report
2024/3/0122:30PRNUSBryan Kobel, CEO of TCBP, Appears on Nationally Syndicated..
2024/2/2807:15PRNUS/C O R R E C T I O N -- TC BioPharm/
2024/2/2722:30PRNUSTCBP Announces Shareholder Update Call on March 5th 2024
2024/2/2223:32PRNUSTCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK..
2024/2/2020:05EDGAR2Form DEF 14A - Other definitive proxy statements
2024/2/1522:30PRNUSTC BioPharm Management to Participate at Upcoming 7th..
2024/2/1504:48EDGAR2Form 8-K - Current report
2024/2/1422:30PRNUSTCBP Provides Shareholder Update and Highlights Upcoming..
2024/2/1005:26EDGAR2Form PRE 14A - Other preliminary proxy statements
2024/1/2923:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/1/2922:30PRNUSTC BioPharm Chief Executive Officer, Bryan Kobel Featured on..
2024/1/1822:30PRNUSTC BioPharm to Present at the Sequire Investor Summit
2024/1/0422:46EDGAR2Form 8-K - Current report
2024/1/0422:30PRNUSTC BioPharm Regains Compliance with Nasdaq Minimum Bid Price..
2024/1/0322:30PRNUSTC BioPharm Announces Additional Cost Reduction Steps to..
2023/12/2222:30PRNUSTC BioPharm Announces Closing of $3.5 Million Public..
2023/12/2207:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/1922:00PRNUSTC BioPharm Announces Pricing of $3.5 Million Public..
2023/12/1914:15EDGAR2Form EFFECT - Notice of Effectiveness
2023/12/1901:15PRNUSTC BioPharm Announces Formation of Commercial Development..
2023/12/1507:20EDGAR2Form F-1/A - Registration statement for certain foreign..
2023/12/1323:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/1320:30PRNUSTC BioPharm Announces Plan to Implement ADS Ratio Change
2023/11/2722:45PRNUSTC BioPharm Announces FDA Clearance of Phase 1B IND for..
2023/11/1500:00PRNUSTC BioPharm Announces Successful Completion of Safety Cohort..
2023/11/0906:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
2023/11/0302:30PRNUSTC BioPharm Announces Streamlined Efficiencies and Reduces..
2023/11/0302:11EDGAR2Form F-3/A - Registration statement by foreign private..
2023/11/0301:57EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/10/2521:00PRNUSTC BioPharm Selects Excellos as CDMO in Anticipation of..
2023/10/2321:00PRNUSTC BioPharm Announces Submission of Investigational New Drug..
2023/9/3005:05EDGAR2Form F-3 - Registration statement by foreign private issuers
2023/9/2721:00PRNUSTC BioPharm to Present at the LD Micro Main Event XVI
2023/9/0521:30PRNUSTC BioPharm Announces Grant Funding in Collaboration with..
2023/9/0206:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
2023/8/3121:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/8/2921:30PRNUSTC BioPharm to Present at H.C. Wainwright 25th Annual Global..
2023/8/2906:25EDGAR2Form F-1 - Registration statement for certain foreign..
2023/8/2305:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/7/3121:30PRNUSTC BioPharm Maintains Nasdaq Listing
2023/7/3121:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/7/2505:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/7/1106:29EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/6/3005:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/5/2422:00PRNUSTC BioPharm to Present at LD Micro Invitational XIII..


Delayed Upgrade Clock